Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New oxygen drug NanO2 tested in patients at risk of ventilator

NCT ID NCT06658535

Symptom relief Sponsor: NuvOx LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a drug called NanO2, which is designed to carry oxygen in the blood. It is being given to 18 hospitalized patients with mild respiratory distress who need extra oxygen but are not yet on a breathing machine. The main goal is to find the safest dose and check for side effects, with a future study planned if this goes well.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
NanO2 (dodecafluoropentane)
What this could lead to
If successful, this could lead to a new way to deliver oxygen to patients with mild breathing problems, potentially reducing the need for mechanical ventilation.
What could go wrong
This is a very early Phase 1 trial with only 18 participants, focused on safety and dosing. It is too small to prove effectiveness, and the treatment may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 18 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Requiring supplemental oxygen but ≤ 6L oxygen by nasal cannula to maintain an oxygen saturation \>92% or PaO2 \>60mmHg * Admitted to a hospital with symptoms of mild RD * Signed informed consent obtained from the subject or subject's legally authorized representative * Agrees to not participate in another clinical trial for the treatment of mild RD through Day 28 Exclusion Criteria: * Presence of extracorporeal membrane oxygenation * Unstable hypertension * History of significantly impaired renal function defined as an eGFR ≤ 30mL/min/1.73m2 (MDRD equation or similar) or impaired hepatic function defined as the presence of decompensated cirrhosis (acute deterioration in liver function characterized by jaundice, ascites, hepatic encephalopathy, hepatorenal syndrome, or variceal hemorrhage) * Presence of pulmonary embolism at baseline * Evidence of right ventricular heart failure * Unstable hemodynamically as defined by receiving 0.5μg/kg/min or greater norepinephrine * Inability to comply with the study procedures * Currently pregnant or breastfeeding * Anticipated discharge from the hospital or transfer to another hospital which is not a study site within 48 hours * History or evidence of any other clinically significant condition that, in the opinion of the investigator, might pose a safety risk to subjects or interfere with study procedures, evaluation, or completion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mild respiratory distress are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Dyspnea

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mild respiratory distress

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Grey Nun Community Hospital

    RECRUITING

    Edmonton, Alberta, T6L 5X8, Canada

  • Hôpital Maisonneuve Rosemont

    RECRUITING

    Montreal, Quebec, H1T 2M4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.